Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06371950
Other study ID # 123608
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 1, 2024
Est. completion date January 1, 2027

Study information

Verified date April 2024
Source Lawson Health Research Institute
Contact Rachel Vander Deen
Phone 519-685-8500
Email Rachel.VanderDeen@lhsc.on.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients having knee replacement surgery regularly experience joint pain and compromised bone quality leading to implant loosening and periprosthetic fractures. The role of the gut microbiome, which is the collection of bacteria and other microbes within the human gastrointestinal tract, is just beginning to be recognized, including its potential effects on pain, infection, and loosening after total joint replacement. Antibiotics are regularly used in orthopaedic surgery to reduce the risk of infection, but they also harm gut microbiota and reduce their potentially beneficial effects. Probiotics may have a role to play in enhancing bone quality and decreasing synovial inflammation after joint replacement surgery, and this study will explore the potential relationship of probiotic use with implant migration, bone density, and patient outcomes. This study is a randomized, controlled, double-blinded trial comparing probiotic use with placebo in post-menopausal women undergoing primary total knee replacement. The main questions it aims to answer are: - to compare implant migration between groups from baseline to six weeks post-surgery - to compare bone density and joint inflammation between groups from baseline to six weeks post-surgery - to compare gut microbiome composition and patient-reported outcome measures between groups from baseline to six weeks post-surgery


Description:

Participants will take a daily probiotic (DE111®) or placebo once daily starting 3 weeks prior to surgery until six weeks after surgery. The following will be completed at baseline and 6 weeks: - Bloodwork - Fecal sample collection - MRSA swab - Patient-reported outcome measures - CT imaging scan In addition, the following will be done: - Intraoperative fluid and tissue collection - Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI) scan at 6 weeks post-surgery Researchers will compare the probiotic and placebo groups for any significant differences in implant stability, bone quality, inflammation, gut microbiome composition, and pain.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date January 1, 2027
Est. primary completion date April 1, 2026
Accepts healthy volunteers No
Gender Female
Age group 55 Years to 75 Years
Eligibility Inclusion Criteria: - Signed informed consent obtained prior to any study-related activities - Postmenopausal female patients of London Health Sciences Centre (LHSC) aged 55-75 years - Scheduled to undergo primary total knee replacement for osteoarthritis Exclusion Criteria: - Unable to understand and respond to the provided questionnaires - Male sex - Inflammatory arthritis - Periprosthetic infection - Prior surgery with hardware insertion in the target knee - Metabolic syndrome - Inflammatory bowel disease - Body mass index <18.5 kg/m2 - Immune-compromised condition (e.g. AIDS, lymphoma, patients undergoing long-term corticosteroid treatment) - Any contraindications for PET-MRI - Allergy to cephalosporin antibiotics

Study Design


Intervention

Dietary Supplement:
Probiotic Formula Bacillus subtilis
5 billion colony forming units (CFU) per day for 9 weeks (3 weeks before surgery to six weeks after surgery)
Other:
Placebo
Placebo

Locations

Country Name City State
Canada London Health Sciences Centre London Ontario

Sponsors (1)

Lead Sponsor Collaborator
Lawson Health Research Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Veterans Rand 12-Item Health Survey (VR-12) Patient-reported outcome measure observing physical and mental health status of patient. Contains 12 questions about 8 health domains: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health. For each domain, the scores range from 0 to 100, with higher scores indicating better health-related quality of life. The minimum score is 0, indicating the lowest level of health or well-being, and the maximum score is 100, indicating the highest level of health or well-being. pre-operative, 6 weeks
Other EuroQol-5D (EQ-5D) Patient-reported outcome measure to assess quality of life on a scale of 0 (worst) to 100 (best). Higher scores indicate better quality of life. pre-operative, 6 weeks
Other Western Ontario McMaster Osteoarthritis Index (WOMAC) Patient-reported outcome measure to assess function, pain and stiffness on a scale of 0 (better function/pain/stiffness) to 100 (worse function/pain/stiffness). Higher scores indicate worse pain, stiffness, and functional limitations. pre-operative, 6 weeks
Other Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP) Patient-reported questionnaire to assess experience with constant and intermittent pain on a scale of 0 (no pain) to 4 (extreme pain). A higher score indicates worse pain. pre-operative, 6 weeks
Other Patient Global Assessment (PGA) Patient-reported scale question to measure global disease activity on a range of 0 (doing very well) to 10 (doing very poorly). A higher score indicates worse condition. pre-operative, 6 weeks
Other University of California, Los Angeles (UCLA) Activity Score Patient-reported outcome measure assessing activity level of patient. Contains a 10-level scale with 1 representing a patient who is inactive and dependent on others, to 10 representing a patient who regularly participates in impact sports. A higher score indicates a greater activity level. pre-operative, 6 weeks
Other Oxford Knee Score - English for Canada Patient-reported outcome measure to assess level of function, activities of daily living, and effects of pain over preceding four weeks, measured with 12 questions each on a scale from 0 (worst outcome) to 4 (best outcome). A higher score represents a better outcome, with total score range from 0-48 pre-operative, 6 weeks
Other Knee Society Score (KSS) Functional outcome measure. Contains 5 sections measuring patient symptoms (none to severe), satisfaction (very satisfied to very dissatisfied), expectation (too high to too low), functional activities, and discretionary knee activities. Functional activities are split into walking and standing (with or without aids and the duration), standard activities (no bother to cannot do), and advanced activities (no bother to cannot do). Discretionary knee activities measure difficulty with the three most important activities for the patient (no bother to cannot do). Higher scores indicate greater patient outcomes. pre-operative, 6 weeks
Other Presence of MRSA Participants will provide a Methicillin-Resistant Staphylococcus Aureus (MRSA) swab sample. Presence of MRSA will be compared over time and between groups. pre-operative, 6 weeks
Other Microbial Diversity - Taxonomic Differences Participants will provide a fecal sample. Microbial DNA will be extracted from the samples for 16S ribosomal ribonucleic acid (rRNA) sequencing so taxonomy can be assigned. The Shannon index for microbial diversity will be calculated and used to determine taxonomic differences in composition and diversity within and between samples. pre-operative, 6 weeks
Other Microbial Diversity - Taxonomic Correlation Participants will provide a fecal sample. Microbial DNA will be extracted from the samples for 16S ribosomal ribonucleic acid (rRNA) sequencing so taxonomy can be assigned. Taxonomic correlations to other clinical and metadata in the study will be determined. pre-operative, 6 weeks
Other Diet and Supplement Questionnaire Patient-reported questionnaire collecting probiotic and supplement consumption habits and gastrointestinal symptoms. Consumption of fermented foods or drinks containing live bacteria will be scored from 0 (no consumption) to 3 (daily consumption) with a higher score indicating greater consumption of live bacteria. Consumption of vitamins and probiotics will be scored from 0 (no consumption) to 3 (daily consumption) with a higher score indicating greater consumption of vitamins and probiotics. Seven gastrointestinal symptoms will be scored from 0 (none) to extreme (4), with a maximum score of 28. A higher score indicates worse gastrointestinal symptoms. pre-operative
Other Histopathology Synovial and tibial plateau samples will be collected intraoperatively and graded for synovitis. Intimal hyperplasia, sub-synovial infiltrate, fibrosis, fibrin deposition, perivascular edema, and vascularization will be graded on a scale of 0 (none) to 3 (severe). A higher score indicates greater synovial inflammation, with a total score range from 0 to 18. intraoperative
Other Immunohistochemistry Synovial and tibial plateau samples will be collected intraoperatively, and the number of macrophages per mm² will be determined. A higher number indicates greater synovial inflammation. intraoperative
Other Inflammatory Blood Marker: C-Reactive Protein Participants will provide a blood sample. Levels of C-Reactive Protein (CRP) will be measured (mg/mL) and compared over time and between groups. Elevated CRP levels are an indicator of inflammation. pre-operative, 6 weeks
Other Inflammatory Blood Marker: Interleukin-1B Participants will provide a blood sample. Levels of Interleukin-1B (IL-1ß) will be measured (pg/mL) and compared over time and between groups. Elevated IL-1ß levels are an indicator of inflammation. pre-operative, 6 weeks
Other Inflammatory Blood Marker: Interleukin-6 Participants will provide a blood sample. Levels of Interleukin-6 (IL-6) will be measured (pg/mL) and compared over time and between groups. Elevated IL-6 levels are an indicator of inflammation. pre-operative, 6 weeks
Other Inflammatory Blood Marker: Interleukin-8 Participants will provide a blood sample. Levels of Interleukin-8 (IL-8) will be measured (pg/mL) and compared over time and between groups. Elevated IL-8 levels are an indicator of inflammation. pre-operative, 6 weeks
Other Inflammatory Blood Marker: Tumor Necrosis Factor Alpha Participants will provide a blood sample. Levels of Tumor Necrosis Factor Alpha (TNF-a) will be measured (pg/mL) and compared over time and between groups. Elevated TNF-a levels are an indicator of inflammation. pre-operative, 6 weeks
Other Inflammatory Blood Marker: Erythrocyte Sedimentation Rate Participants will provide a blood sample. The Erythrocyte Sedimentation Rate (ESR) will be measured (mm/hr) and compared over time and between groups. Elevated ESR is an indicator of inflammation. pre-operative, 6 weeks
Other Inflammatory Blood Marker: Alkaline Phosphatase Participants will provide a blood sample. Levels of Alkaline Phosphatase (ALP) will be measured (units/L) and compared over time and between groups. Elevated ALP levels can indicate inflammation, and may occur during periods of increased bone remodeling or tissue regeneration. pre-operative, 6 weeks
Other Inflammatory Blood Marker: Calcium Participants will provide a blood sample. Levels of calcium will be measured (mmol/L) and compared over time and between groups. Lower calcium levels are an indicator of inflammation. pre-operative, 6 weeks
Other Inflammatory Blood Marker: Albumin Participants will provide a blood sample. Levels of albumin will be measured (g/L) and compared over time and between groups. Decreased levels of albumin are often observed in conditions associated with inflammation. pre-operative, 6 weeks
Other Inflammatory Blood Marker: Urate Participants will provide a blood sample. Levels of urate will be measured (µmol/L) and compared over time and between groups. Elevated urate levels are an indicator of inflammation. pre-operative, 6 weeks
Other Inflammatory Blood Marker: Total Protein Participants will provide a blood sample. Levels of total protein will be measured (g/L) and compared over time and between groups. Elevated protein levels can indicate inflammation. pre-operative, 6 weeks
Other Inflammatory Blood Marker: Creatinine Participants will provide a blood sample. Levels of creatinine will be measured (µmol/L) and compared over time and between groups. Elevated creatinine levels can indicate inflammation. pre-operative, 6 weeks
Other Inflammatory Blood Marker: Vitamin D Participants will provide a blood sample. Levels of Vitamin D will be measured (nmol/L) and compared over time and between groups. Decreased Vitamin D levels are an indicator of inflammation. pre-operative, 6 weeks
Other Inflammatory Blood Marker: White Blood Cell Count Participants will provide a blood sample. Levels of white blood cells (WBC) will be measured (cells/µL) and compared over time and between groups. Elevated WBC levels are an indicator of inflammation. pre-operative, 6 weeks
Other Inflammatory Blood Marker: Red Blood Cell Count Participants will provide a blood sample. Levels of red blood cells (RBC) will be measured (cells/µL) and compared over time and between groups. Decreased RBC levels are an indicator of inflammation. pre-operative, 6 weeks
Other Inflammatory Blood Marker: Hemoglobin Concentration Participants will provide a blood sample. Hemoglobin concentration (Hgb) will be measured (g/L) and compared over time and between groups. Decreased Hgb concentration is an indicator of inflammation. pre-operative, 6 weeks
Other Inflammatory Blood Marker: Hematocrit Percentage Participants will provide a blood sample. Hematocrit (Hct) percentage will be measured (%) and compared over time and between groups. Decreased Hct percentage is an indicator of inflammation. pre-operative, 6 weeks
Other Inflammatory Blood Marker: Platelet Count Participants will provide a blood sample. Platelet counts will be measured (cells/µL) and compared over time and between groups. Elevated platelet counts are an indicator of inflammation pre-operative, 6 weeks
Primary Implant Migration Tibial component migration over time calculated by measuring the position of the component compared to the bone using CT imaging. baseline, 6 weeks
Secondary Bone Density Volumetric bone mineral density over time measured in the anteromedial, anterolateral, posteromedial, and posterolateral regions surrounding the tibial component using CT imaging. baseline, 6 weeks
Secondary Magnitude of 18-F-Fluoroethyl(2-(2-fluoroethoxy)phenyl)-proprionate ([¹8F]FEPPA) Tracer Uptake Magnitude of standardized uptake values (SUV) of the [¹8F]FEPPA tracer uptake in the synovium as measured by PET-MRI. SUV will be calculated using the mean signal intensity, body weight, and decay-corrected injected dose. 6 weeks
See also
  Status Clinical Trial Phase
Completed NCT03995979 - Inflammation and Protein Restriction N/A
Completed NCT03255187 - Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT03577223 - Egg Effects on the Immunomodulatory Properties of HDL N/A
Completed NCT04383561 - Relationship Between LRG and Periodontal Disease N/A
Active, not recruiting NCT03622632 - Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
Completed NCT06216015 - Exercise Training and Kidney Transplantation N/A
Completed NCT04856748 - Nomogram to Diagnose Prostatic Inflammation (PIN) in Men With Lower Urinary Tract Symptoms
Completed NCT05529693 - Efficacy of a Probiotic Strain on Level of Markers of Inflammation in an Elderly Population N/A
Recruiting NCT05415397 - Treating Immuno-metabolic Depression With Anti-inflammatory Drugs Phase 3
Recruiting NCT05670301 - Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases N/A
Recruiting NCT05775731 - Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
Recruiting NCT04543877 - WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study Early Phase 1
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Completed NCT03429920 - Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors N/A
Completed NCT06065241 - Quantifiably Determine if the Botanical Formulation, LLP-01, Has a Significant Clinical Effect on Proteomic Inflammatory Biomarkers and Epigenetic Changes in Healthy, Older Individuals. N/A
Completed NCT05864352 - The Role of Dietary Titanium Dioxide on the Human Gut Microbiome and Health
Completed NCT03318731 - Efficacy and Safety of Fenugreek Extract on Markers of Muscle Damage and Inflammation in Untrained Males N/A
Not yet recruiting NCT06134076 - Comparing Effects of Fermented and Unfermented Pulses and Gut Microbiota N/A
Not yet recruiting NCT06159543 - The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes N/A